This review examines the pathophysiology of isolated systolic hypertension, changing medical perspectives on this condition as a cardiovascular risk factor in the community and evolving evidence of it being an independent risk factor for perioperative morbidity and mortality.
Hypertension is regarded as an added risk in anaesthesia 1, 2 . Attitudes to the treatment of hypertension have evolved over time. In the mid 1950s and 60s, the view of antihypertensives and anaesthesia was variable, with some advocating continuation of antihypertensive medication and others recommending cessation of medication prior to surgery. Continuation of antihypertensive medication through the perioperative period has prevailed 2 . Studies supporting this practice have demonstrated greater perioperative haemodynamic stability in association with general anaesthesia and surgery in patients with treated hypertension compared to untreated hypertension 1, 2 . Therapy has traditionally focused on control of diastolic blood pressure, rather than on systolic blood pressure. Recent data from large clinical trials 3, 4 have supported data from large observational studies [5] [6] [7] [8] [9] [10] [11] showing a closer association of systolic hypertension with both coronary heart disease and stroke compared with diastolic hypertension This has led to a shift to recommendations for the more aggressive treatment of isolated systolic hypertension, especially in patients over 65 years 8, 12, 13 . It has also been suggested that anaesthetic assessment and approach should be studied and perhaps revised, in light of these developments 14, 15 . This review examines the pathophysiology of isolated systolic hypertension as well as the medical and anaesthetic evidence for P. WONGPRASARTSUK, J. W. SEAR Anaesthesia and Intensive Care, Vol. 31, No. 6, December 2003 this condition as an independent risk factor for perioperative morbidity and mortality.
Pathophysiology
Arteries have two functions: to serve as conduits, distributing blood, and a cushioning function converting pulsatile ventricular ejection to a more continuous flow peripherally. Blood pressure can be thought of in two dimensions. The first, mean arterial blood pressure, maintains a steady flow of blood into the arterial vessels and is a function of systemic vascular resistance and cardiac output. The second, pulsatile component of blood flow is represented by pulse pressure, being the difference between systolic and diastolic blood pressures 16 . The magnitude and nature of this pulsatile flow is determined by the elastance of large arteries and the timing of reflected pressure waves. Following ventricular systole, the systemic arterial tree accommodates all the stroke volume ejected by the left ventricle. In normal systole, 40% of left ventricular stroke volume passes to the periphery, the remainder distends the aorta and major arteries which act as capacitance vessels. During diastole, the elastic recoil in the aorta and major arteries propels the remaining 60% of stroke volume to the periphery. Ventricular ejection results in pressure waves which move out to the periphery. These waves are reflected from peripheral branch points or kinks in the arterial tree back toward the ascending aorta.
Increased arterial stiffness, due to aging or pathology, decreases arterial distensibility. This produces a complex interaction between the proportion of stroke volume propelled forwards, the amplitude and forward velocity of the arterial pulse wave, as well as the timing of the return of the reflected pulse wave. These changes are measured in alterations in systolic, diastolic and pulse pressures. A greater proportion of stroke volume is ejected forward during ventricular systole when there is decreased arterial distensibility increasing the amplitude of the arterial pressure wave, and thus the systolic blood pressure. Less blood and therefore less potential energy is stored for forward flow during ventricular diastole. Thus for a given heart rate and peripheral vascular resistance, diastolic pressure is lower. Arterial stiffening also increases the velocity of pressure waves. It is thought that an earlier return of reflected waves, during systole, rather than diastole, augments the systolic component of the incident wave 16 . This results in increased systolic pressure, increased pulse pressure and decreased diastolic pressure, for a given peripheral vascular resistance 17 .
Data from the Framingham Heart study 7, 16, 17 , which has followed a cohort of men and women since 1948, illustrate these changes in blood pressure levels with age and arterial stiffening. Normotensive and hypertensive subjects showed a consistent linear rise in systolic blood pressure with age (30 to 84 years old). diastolic blood pressure and mean arterial pressure rise concurrently in keeping with systolic pressure until mid 50-60 year age. After this a divergent pattern emerges. Diastolic pressure declines and pulse pressure increases with age and mean arterial pressure plateaus ( Figure 1 ). There are three haemodynamic phases in relation to blood pressure and aging. In all three phases systolic pressure rises steadily with age. Under age 50, there is predominance of a steady rise in vascular resistance, reflected by a steady increase in diastolic pressure and mean arterial pressure. By 50 to 60 years, increased vascular resistance and arterial stiffness increase in parallel resulting in constant diastolic pressure, plateauing mean arterial pressure and increased pulse pressure. Over age 60, large artery stiffness predominates, with falling diastolic pressure, and rising pulse pressure 8, 17 .
Increases in systolic pressure and pulse pressure increase the sheer stress and fatigue on arterial walls, accelerating arterial damage, exacerbating agerelated changes and atherosclerosis, creating a vicious cycle of plaque formation and rupture, further blood vessel damage and loss of arterial distensibility. Increased stroke volume ejected during systole, with consequent loss of stored potential energy in arteries for diastolic flow contributes to a fall in diastolic pressure. Systolic pressure is augmented due to early return of the reflected pressure wave, thus increasing aortic afterload during ventricular systole, which may cause left ventricular hypertrophy. Combined with lower diastolic pressure, left ventricular hypertrophy may compromise subendocardial myocardial perfusion 16 . Pre-existing hypertension accelerates these changes.
Medical Evidence and Changing Management of Hypertension in the Community

Population based studies
Isolated systolic hypertension with systolic pressure >160 mmHg and diastolic pressure <90 mmHg is thought to be the most common form of hypertension in people over 65 years. As this age group is increasing in absolute numbers and proportion of the community in developed countries, isolated systolic hypertension may become the most prevalent form of hypertension 12 . The Framingham and other popula-tion-based epidemiological studies suggest that this condition is an independent risk factor for coronary heart disease, stroke and end-stage renal disease and is more closely associated with risk than diastolic blood pressure.
Studies concentrating on diastolic blood pressure alone have established elevated blood pressure as a risk factor for coronary heart disease 18, 19 . Further analysis of the Framingham 30-year study data indicates that systolic blood pressure is a strong and consistent predictor of coronary heart disease in both men and women, over several age strata 5, 7 . The Multiple Risk Factor Intervention Trial (MRFIT) cohort also provides evidence of a relationship between the level of systolic blood pressure and coronary heart disease. This study followed 361,662 middle-aged U.S. men over 11.6 years, aged 36 to 57 years when first screened. There were 7,150 coronary heart disease deaths recorded. For every 10 mmHg rise in systolic blood pressure there is a corresponding rise in relative risk of coronary heart disease death. (Figure 2 ). It was observed in this population, from middle age onwards that systolic blood pressure had a stronger relationship with coronary heart disease risk than diastolic pressure. For every level of diastolic pressure, systolic pressure was related to cardiovascular risk in a continuous and graded manner 9 . Comparing the lowest 10% of blood pressure with the highest 10%, the relative risks of coronary heart disease death were 3.66 for systolic blood pressure and 2.78 for diastolic (P<0.001). Other studies have consistently supported these observations 5, 7, 8 .
Population data and pooled clinical trial data 621 ANAESTHESIA AND ISOLATED SYSTOLIC HYPERTENSION demonstrates that elevated diastolic blood pressure results in an increased risk of stroke 18, 19 . Most prospective population studies suggest that systolic pressure is more strongly associated with stroke risk than diastolic 5 . In the Copenhagen City Heart study 19698 men and women were followed over a 12-year period. After adjusting for age, gender, smoking, diabetes mellitus, body mass index and serum cholesterol, this study concluded that systolic blood pressure is a better predictor of stroke risk than diastolic pressure. Compared with normotensive individuals, for women the relative risk of stroke with isolated systolic hypertension was 4.1 (95% CI=2.3-7.3) and with systolic-diastolic hypertension 3.2 (95% CI=2.0-5.3). The relative risks of stroke associated with isolated systolic hypertension and systolic-diastolic hypertension were similar for men (for isolated systolic hypertension RR=2.1, 95% CI=1.1-4.2; for systolic-diastolic hypertension RR=2.0, 95% CI= 1.2-3.5). In contrast men and women with isolated diastolic hypertension and borderline systolic hypertension were not at significantly elevated risk of stroke 11 . In the MRFIT cohort, elevated systolic blood pressure was also found to be a stronger predictor of fatal stroke than diastolic pressure. After controlling for other risk factors and confounders (age, race, income, serum cholesterol, cigarettes per day and diabetes) for every 10 mmHg rise in blood pressure (systolic and diastolic pressure) there was a progressive rise in relative risk of fatal stroke. This was greater with elevations in systolic than diastolic pres-sure. Therefore for men with systolic pressure in the highest two deciles of blood pressure category (142-150 mmHg and >150 mmHg) the relative risks of fatal stroke were 4.44 and 8.21 respectively. In contrast, men in the two highest deciles of diastolic pressure category (92-97 mmHg and (98 mmHg) had relative risks of 2.78 and 4.45 respectively (Figure 3 ). In a study population of 8006 Japanese-American Hawaiian men followed for 20 years, isolated systolic hypertension had the greatest impact on the risk of stroke, followed by systolic-diastolic hypertension. Men with isolated diastolic hypertension had only a slightly higher relative risk of stroke compared with normotensive individuals. This impact was more significant in younger, than older men, suggesting that while isolated systolic hypertension is more common in older men, in younger men it is associated with a higher relative risk of stroke 10 .
Hypertension is regarded as an important risk factor for the development and progression of chronic renal disease 5 . A 16-year follow-up of 332,544 men found a strong, graded relation between hypertension and chronic renal disease. This was independent of age, race, income, history of medication for diabetes mellitus, history of myocardial infarction, serum cholesterol, and cigarette smoking. When both systolic and diastolic blood pressure variables were considered together, the estimated risk of chronic renal disease was higher with elevated systolic blood pressure 20 
Clinical Trials
Over recent years, large prospective randomized clinical trials provide evidence that treating isolated systolic hypertension helps reduce the risk of stroke and coronary heart disease. Two major multicentre trials, Systolic Hypertension in Europe (Syst-Eur) and Systolic Hypertension in the Elderly (SHEP), have been influential in providing this evidence.
In SHEP, a multi-centre clinical trial, 4736 subjects were recruited in 16 centres throughout the United States 3,13 . This trial was designed primarily to assess the effect of treating isolated systolic hypertension (defined as SBP >160 mmHg and DBP <90 mmHg) in the elderly (age >60 years) on the risk of fatal and non-fatal stroke. The target blood pressure was based on baseline systolic blood pressure. If baseline BP was ≥180 mmHg, target reduction was to <160 mmHg. If baseline blood pressure was 160 to 179 mmHg, the aim of treatment was a reduction of at least 20 mmHg. Participants were assigned to either active treatment or placebo. The active treatment consisted of a stepped care program, increasing drug dosage and using combined therapy as required.
Step 1: chlorthalidone at 12.5 mg increasing to 25 mg if necessary. Step 2: atenolol 25 mg, then 50 mg. If β-blockade was contraindicated, reserpine (0.05-0.10 mg) was substituted. Participants were treated and followed for five years. The primary endpoint of the trial was fatal and non-fatal stroke with secondary end points being fatal and non-fatal cardiovascular events. The results of this trial showed a 36% reduction in stroke risk (P=0.0003), 25% reduction in coronary heart disease (P=<0.05) and 32% fall in total cardiovascular disease events (P=<0.05) in the active treatment group compared to the placebo group 3 .
Syst-Eur also assessed the effect of treating isolated systolic hypertension on the incidence of stroke 4 . Trial methodology differed from SHEP. Qualifying blood pressure and age were similar to SHEP, though medical intervention differed. Participants were stratified for centre, gender and previous cardiovascular complications and randomly allocated to receive active treatment or placebo. Active treatment was given in a stepwise manner to achieve a goal of systolic pressure <150 mmHg. Participants randomized to active treatment received nitrendipine (10 to 40 mg) with the possible addition of enalapril (5 to 20 mg) and hydrochlorthiazide. The primary endpoints were fatal and non-fatal stroke with secondary endpoints of other cardiovascular compli-623 ANAESTHESIA AND ISOLATED SYSTOLIC HYPERTENSION cations including coronary heart disease. Participants were followed up for a median of two years. The results of this trial at two years showed a reduction in total stroke of 43% (P=0.003), with non-fatal stroke falling by 44% (P=0.007) in the active treatment group. Fatal and non-fatal cardiac endpoints, including sudden death were reduced by 26% (P=0.03) in those receiving active treatment.
Two quantitative meta-analyses have both concluded treating isolated systolic hypertension confers a protective effect against stroke and probably reduces coronary heart disease risk. Staessen and coworkers conducted a systematic review including eight controlled trials incorporating 15693 subjects in their analysis. They concluded that drug treatment is justified in older people where the systolic blood pressure is ≥160 mmHg and that the absolute benefit is larger in men, patients ≥70 years old, those with a history of previous cardiovascular complications and those with a wider pulse pressure. The pooled reduction in risk of the treated group compared to placebo of all cardiovascular complications (fatal and nonfatal) was 26% (95% CI=17-34; P<0.0001); 30% (95% CI=18-41, P<0.0001) for stroke and 23% (95% CI=10-34, P=0.001) for coronary heart disease. After correction for confounding factors, the relative hazard rate associated with a 10 mmHg increase in systolic pressure was 1.26 for total mortality and 1.22 for stroke 6 . Another meta-analysis pooled 10 randomized, controlled trials (total n=18,542). The pooled risk reduction in those receiving active treatment was 25% (95% CI=15-34, P<0.001) for all cardiovascular disease deaths; 37% (95% CI=28-45, P<0.001) for all stroke and 21% (95% CI=10-31, P<0.001) for all coronary heart disease 5 . Sander's meta-analysis provides good evidence that aggressive antihypertensive treatment in these elderly patients produces a reduction in combined fatal and non-fatal stroke, fatal and non-fatal cardiovascular events and total mortality. The method of treatment appeared to be less important than being treated 21 .
Those with a lower diastolic blood pressure may be most at risk. In a meta-analysis of over 7500 patients a lower diastolic pressure was associated with a higher death rate. Independent of systolic blood pressure, the diastolic was shown to be inversely correlated with total mortality, highlighting the importance of pulse pressure as a risk factor 6 . In a metaanalysis based on the control patients from seven clinical trials including those with systolic-diastolic hypertension and isolated systolic hypertension, Gasowski and co-workers showed that a widening of the pulse pressure was the main prognosticator for cardiovascular mortality and fatal coronary events 22 .
These analyses suggest that pulse pressure rather than systolic blood pressure is the best predictor of risk.
Though there is general agreement that isolated systolic hypertension, especially in the older age group (>60 years), should be treated, there is some debate about the blood pressure level that should be treated, the goal of blood pressure reduction and the best drug treatment regimen 12, [23] [24] [25] [26] [27] . The influential U.S. based Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure state in their most recent report (JNC VI) that systolic hypertension is defined as systolic blood pressure ≥140 mmHg. Treatment is recommended at this level 27 . Port and co-workers using a different mathematical model to previous studies suggest the Framingham data does not actually support a cutoff value of 140 mmHg for everyone. Using this approach, a re-analysis of the Framingham data showed cardiovascular risk increased sharply with systolic pressure greater than the 80th centile of blood pressure for age and gender (above approximately 158 to 170 mmHg). Below the 70th centile cardiovascular risk appears to be constant and low. Between the 70th and 80th centiles (130 to 170 mmHg) cardiovascular risk may be slightly increased, but the model was unable to show at what point risk increased. It is suggested that by treating all patients at 140 mmHg, an excess number of people may be subjected to treatment with little reduction in excess cardiovascular risk 25 . To date no prospective, randomized, placebo-controlled clinical trial demonstrates significant benefit of treating systolic pressure between 140 and 160 mmHg. The major clinical trials supporting the treatment of systolic blood pressure had a qualifying systolic pressure of 160 mmHg and aimed to reduce it to below this target 3, 4 .
There is also concern about excessive lowering of the diastolic pressure as a side-effect of treating isolated systolic hypertension, a so-called J-curve effect, with excessive cardiovascular risk if the blood pressure is lowered too vigorously 12, 26 . An increase in orthostatic hypotension may be a significant adverse effect of antihypertensive therapy 23 . Data from SHEP and other studies suggests that if the diastolic pressure is lowered to <65-70 mmHg in the course of treating isolated systolic hypertension, there is an increase in stroke and other cardiovascular events 12 . Results of another recent trial suggest the optimal diastolic pressure is around 86 mmHg 26 . Therefore caution is advocated to not allow the diastolic pressure to be excessively lowered in the treatment of isolated systolic hypertension in patients with already low diastolic pressure.
Anaesthesia and Hypertension
There are few reports examining the influence of hypertension on morbidity and mortality in surgical patients. Haemodynamic instability accompanied by ECG evidence of myocardial ischaemia has been observed in both treated and untreated hypertensive patients in association with general anaesthesia 1, 2, 28 . In a study of general anaesthesia in 17201 patients, Forrest and colleagues found 17 significant predictors of severe adverse cardiovascular events. Preoperative hypertension was found to be associated with an increased risk of perioperative bradycardia, tachycardia and hypertension 29 . Demonstrating a clear association between hypertension and adverse postoperative outcome has been more difficult. One of the main problems is the low frequency with which complications occur.
In a study of 676 patients undergoing elective surgical procedures, Goldman and Caldera were unable to demonstrate that a history of mild to moderate hypertension was associated with the development of cardiac arrhythmias, myocardial ischaemia, heart failure or renal failure 30 . There is conflicting evidence for an association between hypertension and adverse outcome. In a meta-analysis of 24 studies examining hypertensive disease as a univariate marker, Howell et al 31 found an overall association with cardiac death and complications (Odds Ratio (OR)=1.25; 95% CI 1.07-1.47), though this is probably not clinically significant. This analysis did not take into account other confounding factors and heterogeneity between the different studies included in the meta-analysis. A subgroup analysis of data from studies published from 1990 onwards failed to confirm an association (OR= 1.03; 95% CI 0.81-1.30).
There are also few data examining the possible association between hypertensive disease and postoperative mortality 32 . In a series of case-control studies, Howell and co-workers [33] [34] [35] showed an association between preoperative history of hypertension and postoperative cardiovascular death within 30 days of elective surgery. Such an association between hypertension and postoperative cardiovascular death could not be demonstrated in association with urgent or emergency surgery. More recent data from the same epidemiological database (the Oxford Record Linkage Study: ORLS) for the period 1991-1998 have failed to confirm the same association for elective surgical patients. This may reflect changes in the severity of hypertensive disease, changes in drug therapies, changes in perioperative monitoring and anaesthetists' response to haemodynamic changes, as well as in anaesthetic techniques 36 .
Examination of surrogate endpoints for adverse cardiac outcome reveals a more consistent association between hypertension and perioperative cardiovascular complications. Myocardial ischaemia has been detected in lead V 5 of the ECG in patients with a history of hypertension undergoing general anaesthesia. These transient episodes were associated with tachycardia and noxious stimuli, such as laryngoscopy and intubation 2, [37] [38] [39] . In 325 elective non-cardiac surgical patients who underwent ambulatory ECG monitoring preoperatively, hypertension despite long-term maintenance treatment was associated with the presence of silent myocardial ischaemia 40 . Other studies have both supported 41, 42 and refuted 43, 44 associations between hypertension and myocardial ischaemia. Sear et al 45 found no association between hypertension and myocardial ischaemia in a multivariate analysis which included the confounders of beta-adrenoceptor blockade, calcium channel entry blockade and vascular surgery.
In general it is accepted that hypertension is associated with increased operative risk 14 . Ideal medical control of hypertension may take weeks to months to achieve. Preoperative anaesthetic care of the hypertensive patient is based upon the balance between perceived operative risks for a particular blood pressure versus the urgency of surgery. One recommendation is that if the diastolic pressure is less than or equal to 110 mmHg and stable, elective surgery may proceed without delay provided the perioperative blood pressure is monitored closely and hyper-or hypotensive episodes are treated appropriately 30 . Another approach is if the diastolic pressure is greater than 100 mmHg, with or without antihypertensive therapy, then elective surgery should be deferred until the blood pressure is under better control 15 .
These suggestions do not address the anaesthetic management of isolated systolic hypertension. This condition is common, affecting 8 to 10% of the population over 60 years old and according to some U.S. studies, is present in more than 50% of hypertensive patients aged over 65 years. In the U.K., hypertension, including isolated systolic hypertension is seen in over 50% of the population aged greater than 60 years 46 . There is scant data on the interaction of anaesthesia and hypertension in these patients.
In a recent editorial, Prys-Roberts proposes the only justification for cancelling patients with isolated systolic hypertension is to treat risk factors such as cardiac failure and other intercurrent illness 15 . There is only one study that has suggested that it is a risk factor for the development of postoperative silent 625 ANAESTHESIA AND ISOLATED SYSTOLIC HYPERTENSION myocardial ischaemia. This study followed 140 patients with the aim of examining the role of a number of risk factors in the development of silent myocardial ischaemia after general anaesthesia for general and vascular surgery. A history of hypertension was associated with increased risk of postoperative silent myocardial ischaemia (odds ratio 2.58%, 95% CI=1.12-5.96) with a linear trend to increasing risk with increasing admission systolic pressure (odds ratio 1.20, 95% CI=1.01-1.42 for each 10 mmHg increase in SBP). Risk factors associated with postoperative silent myocardial ischaemia were found to be: preoperative silent myocardial ischaemia, preadmission diagnosis of hypertension, elevated admission systolic blood pressure and planned vascular surgery. Diastolic pressure, although found to be a significant risk factor when univariate analysis was used, did not change the regression model if either systolic pressure or preoperative silent myocardial ischaemia were added to the model 41 .
What of the interaction between isolated systolic hypertension and anaesthesia? There are anecdotal reports of hypotension associated with induction of anaesthesia and marked pressor responses to noxious stimuli. A different approach was used to study the effects of different antihypertensive treatments on haemodynamic responses to induction of anaesthesia, laryngoscopy and intubation 47 . No significant differences were found in the effects of different treatments on the hypotensive response to induction of anaesthesia or the pressor response to laryngoscopy and intubation apart from the chronotropic response to noxious stimuli which was obtunded in the group receiving β-adrenoceptor blocking drugs. Re-analysis of the data from patients aged >65 years comparing patients with isolated systolic hypertension (systolic pressure >160 mmHg) with patients with combined systolic and diastolic hypertension (DiastHT; BP >160/90 mmHg) showed that there was no difference in the maximum haemodynamic response to induction of anaesthesia or laryngoscopy and intubation ( Table 1 ). The 27 patients with isolated systolic hypertension included both treated (diuretics or calcium channel blockers) and untreated patients, and the 17 patients with diastolic hypertension were all treated (β-adrenoceptor blockade, ACE inhibitors, calcium channel blockers, diuretics and α-methyldopa; as single or combination therapy).
Tamborini et al recently reported that in the patient with isolated systolic hypertension, induction of anaesthesia results in a fall in both blood pressure and coronary blood flow (the latter being in the order of 30% decrease) 48 . Aronson et al have shown that isolated systolic hypertension was associated with adverse cardiovascular outcomes (left ventricular dysfunction, cerebrovascular events, renal insufficiency or failure, and all-cause mortality) in a prospective epidemiological study of 2417 patients undergoing coronary artery bypass grafting. Isolated systolic hypertension was present in 29.6% of the patients, and the unadjusted odds ratio for the association of isolated systolic hypertension and adverse outcomes was 1.4 (CI=1.1-1.7). After adjusting for other potential risk factors, the increased risk associated with isolated systolic hypertension was still 30% 49 .
CONCLUSION
Isolated systolic hypertension is set to become the most prevalent form of hypertension in the developed world due to an aging population. Good evidence in the form of population studies, large multicentre clinical trials and quantitative meta-analysis of major trials has accumulated showing isolated systolic hypertension to be a risk for stroke and coronary heart disease as well as cardiac and all-cause mortality. It may also be a risk factor for renal failure. There is also evidence that those with a lower diastolic pressure (i.e. wider pulse pressure) are at most risk 6;22;50-55 . If the anaesthetic preoperative approach to isolated systolic hypertension uses rules and guidelines based on systolic-diastolic hyperten- Haemodynamic response to laryngoscopy and intubation sion, those at highest medical risk may be missed; that is, patients with isolated systolic hypertension and normal or low diastolic pressure. It is informative to note that comment on isolated systolic hypertension does not appear in recent American College of Cardiology/ American Heart Association Guidelines about hypertension 56 . Data about the interaction of anaesthesia and isolated systolic hypertension is scarce and the premise that this is a risk factor per se in relation to anaesthesia needs further evaluation. There is clear need for studies using systolic pressure and pulse pressure as markers for perioperative risk, especially with the aging population we are being asked to anaesthetize.
